Dr. Meric-Bernstam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-745-7296
Education & Training
- University of MichiganResidency, Surgery, 1991 - 1998
- Yale School of MedicineClass of 1991
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2023 - 2026
- GA State Medical License 2023 - 2026
- TN State Medical License 2023 - 2026
- TX State Medical License 1999 - 2026
- AL State Medical License 2023 - 2025
- LA State Medical License 2023 - 2025
- American Board of Preventive Medicine Clinical Informatics
- American Board of Surgery Surgery
- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2011-2013
- Join now to see all
Clinical Trials
- Bevacizumab in Multiple Phase I Combinations Start of enrollment: 2007 Oct 10
- Axillary Reverse Mapping for Invasive Carcinoma of the Breast Start of enrollment: 2008 Mar 01
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy Start of enrollment: 2009 Mar 30
- Join now to see all
Publications & Presentations
PubMed
- Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, Timothy A Yap, Jordi Rodon
Clinical Cancer Research. 2025-04-01 - A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies.Jibran Ahmed, Anne Knisely, Carlos Torrado, Bettzy Stephen, Yali Yang
The Oncologist. 2025-03-10 - Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.Funda Meric-Bernstam, Aditya Bardia, Paolo Bossi, Giampaolo Bianchini, Frances Gatlin
The Oncologist. 2025-03-10
Lectures
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.2019 ASCO Annual Meeting - 6/1/2019
- Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Single agent activity of ZW25, a HER's targeted bispecific antibody, in heavily pretreated HERs' expressing cancers.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- Join now to see all
Press Mentions
- MD Anderson Unveils Breakthrough Research Findings – February 10, 2025February 10th, 2025
- Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human TrialSeptember 13th, 2024
- MD Anderson Research Highlights for May 8, 2024May 8th, 2024
- Join now to see all
Grant Support
- Training of Academic Surgical OncologistsUNIVERSITY OF TX MD ANDERSON CAN CTR1994–2028
- A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)METHODIST HOSPITAL RESEARCH INSTITUTE2022–2027
- Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffoldUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2022–2027
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUNIVERSITY OF TX MD ANDERSON CAN CTR2014–2026
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: